FindTrial
Sign In

Which works better in melasma patients modified kligman with oral tranexamic acid or modified kligman alone

A comparative study of modified kligman regimen versus combination of modified kligman with oral tranexamic acid in the treatment of melasma - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/09/073872
Enrollment
170
Registered
2024-09-13
Start date
Unknown
Completion date
Unknown
Last updated
2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L811- Chloasma

Interventions

Intervention1: oral tranexamic acid with modified kligman regimen: oral tranexamic acid 250 mg 12 hrly with local application of modified kligman regimen over lesion for 2 hrs at night for total durat

Sponsors

Dr Anuradha Gupta
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: : 1- Patients aged between 20 to 60yrs. 2- Patients diagnosed with Melasma and not taking oral/topical medication in last 3 months. 3- Patients who give consent for study.

Exclusion criteria

Exclusion criteria: 1. H/o Thrombotic events, Stroke, Myocardial Infarction. 2. Pregnant women, menstrual irregularities. 3. Patients taking oral contraceptives 4. Patients with sensitive skin (burning sensation, allergic to any topical creams). 5. Photosensitivity disorders (SLE, porphyria, drugs). 6. Underwent any recent surgeries within a period of (3 months) and undergoing any cosmetic procedure. 7. Patients not willing to participate in study.

Design outcomes

Primary

MeasureTime frame
age duration gender type of melasma location of melasma size of lesion MSI score Timepoint: start of therapy—

Secondary

MeasureTime frame
age duration gender type of melasma location of melasma size of lesion MSI scoreTimepoint: at the end of 12 th week—

Countries

India

Contacts

Public ContactDr anuradha gupta

Peoples college of medical science and research center

dermatology.hod@gmail.com9981346039

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026